OakChart

Korsana Biosciences Inc

KRSAHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:59 PM ET

31.84+0.73 (2.35%)
2026-11-12 04:31 CET
Market cap
1,450.04 USD m
Revenue, TTM
1.02 USD m
Net income, TTM
-52.16 USD m
Free cash flow, TTM
-51.31 USD m
EPS diluted, TTM
-13.07
P/E
-
Compare

Price

KRSA against its 20, 50 and 200-day averages
2050200missearnings
20.0030.00206K411KVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26KRSAclose 31.8420-day 31.4150-day 31.66200-day 22.8031.84

46.4% under the 52-week high of 59.36 on 1 Apr 2026. 52-week low 7.19 on 9 Feb 2026. Last 15 sessions, 18.6% high to low

Volume 1.87× normal · the line is the 50-bar volume average

Profile

KRSA
52-week range, 47% of the way up
7.1959.36

Korsana Biosciences, Inc. is a biopharmaceutical company, which engages in discovering and developing novel therapies to reduce the burden of neurodegenerative diseases. Its portfolio includes the KRSA-028 pipeline. The company was founded in 2024 and is headquartered in Waltham, MA.

Employees1
IPOMar 18, 2019
Beta1.83
ATR, 14d2.36
Rel volume1.87
Short float0.37%
Insider own1.27%
Inst own21.42%

Snapshot

6 groups

Valuation

Index-
Market Cap1.45B
Enterprise Value1.02B
Income-52.16M
Sales1.02M
Book/sh8.60
Cash/sh10.02
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees1
IPOMar 18, 2019

Ratios

P/E-
Forward P/E-
PEG-
P/S1421.60
P/B3.70
P/C3.18
P/FCF-
EV/EBITDA-
EV/Sales1000.04
Quick Ratio10.42
Current Ratio10.42
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-13.07
EPS next Y-
EPS next Q-0.90
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y62.05% 53.53%
Sales past 3/5Y91.14% -2.01%
EPS Y/Y TTM-146.07%
Sales Y/Y TTM-64.10%
EPS Q/Q-62.02%
Sales Q/Q-100.00%
EarningsNov 05 BMO
EPS/Sales Surpr.-276.62% -

Ownership

Insider Own1.27%
Insider Trans0.00%
Inst Own21.42%
Inst Trans37.41%
ROA-22.08%
ROE-24.48%
ROIC-12.49%
Gross Margin-
Oper. Margin-5277.27%
Profit Margin-5088.39%
SMA201.38%
SMA500.58%
SMA20039.63%
Trades-

Technical

Shs Outstand45.54M
Shs Float44.96M
Short Float0.37%
Short Ratio1.87
Short Interest0.17M
52W High59.36 -46.36%
52W Low7.19 343.07%
Volatility5.99% 7.30%
ATR (14)2.36
RSI (14)51.97
Beta1.83
Rel Volume1.87
Avg Volume89.45K
Volume167,291

Performance

Perf Week4.19%
Perf Month0.57%
Perf Quarter16.33%
Perf Half Y45.32%
Perf YTD258.16%
Perf Year182.52%
Perf 3Y107.25%
Perf 5Y-91.42%
Perf 10Y-
Recom1.00
Target Price53.00
Prev Close31.11
Price31.84
Change %2.35%

Analyst ratings

latest 8 of 8
DateActionAnalystRating changeTargetImplied
Oct 05, 2026InitiatedWWedbushOutperform$44+38.2%
Sep 28, 2026InitiatedGGuggenheimBuy$70+119.8%
Sep 14, 2026InitiatedTTD CowenBuy
Sep 14, 2026InitiatedSStifelBuy$43+35.1%
Sep 11, 2026InitiatedUUBSBuy$55+72.7%
Oct 20, 2021InitiatedTTruistBuy$14-56.0%
Sep 24, 2021InitiatedCCantor FitzgeraldOverweight$7-78.0%
Jun 03, 2019InitiatedCCredit SuisseNeutral

Peers

Mkt cap
TickerCompanyMkt cap
DNLIDenali Therapeutics Inc3.16B
AVXLAnavex Life Sciences Corp98.26M
PRTAProthena Corp Plc448.28M
ANVSAnnovis Bio Inc36.41M
ACIUAC Immune SA230.01M
ALECAlector Inc391.55M
ABOSAcumen Pharmaceuticals Inc16.64M
CGTXCognition Therapeutics Inc64.42M
BIIBBiogen Inc37.46B
INMBINmune Bio Inc34.05M

Insider trading

6 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
MICHAEL HIGGINSDirectorOct 22 '26Proposed Sale32.001,10735,424Oct 22 04:06 PM
ERROL B DE SOUZADirectorSep 23 '26Proposed Sale34.994,903171,556Sep 23 04:50 PM
ERROL B DE SOUZADirectorSep 22 '26Proposed Sale34.991003,499Sep 22 04:56 PM
ERROL B DE SOUZADirectorSep 18 '26Proposed Sale34.992,13974,844Sep 18 04:49 PM
CHICKO RHONDA M.Chief Financial OfficerAug 14 '26Option Exercise2.3525,00058,87525,018Aug 18 05:27 PM
Graul Regina MargaretSee RemarksAug 14 '26Option Exercise3.3055,849184,302156,152Aug 18 05:21 PM

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B
ONEQFidelity Nasdaq Composite Index ETFAUM: 10.35B
DFSUDimensional US Sustainability Core 1 ETFAUM: 2.38B
DXUVUS Vector Equity Portfolio ETF Class SharesAUM: 665.71M
DFACU.S. Core Equity 2 Portfolio-ETF Class SharesAUM: 49.14B
DCORUS Core Equity 1 Portfolio ETF Class SharesAUM: 3.65B

News

latest 14 of 100

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-3.190-0.847-3.2870.000.005
2026Q22026-08-11-0.093--2.8900.00--
2025Q42026-03-25-2.660-2.660-1.4640.100.101
2022Q22022-08-09-0.300--43.1280.36--
2022Q12022-05-05-42.000-50.400-41.8400.710.551
2021Q42022-02-24-46.200-42.000-34.7490.530.901
2021Q32021-11-09-36.400-49.700-36.5110.351.502
2021Q22021-07-30-63.000--63.4473.00--
2020Q42021-02-25-75.600-26.880-79.064---
2020Q32020-11-05-95.200-78.960-82.057---
2020Q22020-08-03-98.000-120.82-98.4050.70-1
2020Q12020-05-04-102.2-121.66-102.35---
2019Q42020-03-12-133-124.88-132.171.480.471
2019Q32019-12-27-7.000-9.096-139.41.40-1
2019Q22019-11-12-165.2-117.04-164.841.63-1
2019Q12019-05-30-16.520--190.99---

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2018FY-16,135--588.840.00-
2019FY-628.97-693-628.974.513.50
2021FY-184.8-193.2-184.723.944.31
2022FY-141.4--141.41.63-
2025FY-9.380-9.380-7.7641.101.10
2026FY--8.400--0.00
2027FY--6.930--0.00

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-054000.000.000.00
2026Q4S2026-10-024000.000.000.00
2026Q4S2026-09-253000.000.000.00
2026Q4S2026-09-112000.000.000.00
2026Q4S2026-09-101000.000.000.00
2026Q4R2026-11-05523-0.90-1.05-0.72
2026Q4R2026-10-02500-0.94-1.13-0.67
2026Q4R2026-09-25400-1.01-1.13-0.94
2026Q4R2026-09-11300-1.03-1.13-0.95
2026Q4R2026-09-10100-1.13-1.13-1.13
2026Q4E2026-11-05523-0.90-1.05-0.72
2026Q4E2026-10-02500-0.94-1.13-0.67
2026Q4E2026-09-25400-1.01-1.13-0.94
2026Q4E2026-09-11300-1.03-1.13-0.95

Estimate history

EPS, annual-479.864-588.843-628.967-358.263-184.717-141.991-62.919-8.498-7.764-13.0746
Period201720182019202020212022202320242025TTM
EPS, quarterly-2.0041.457-3.914-0.739-2.119-1.464-5.289-2.89-3.432
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual004.5072.2963.9420.297022.0741.02
Period201720182019202020212022202320242025TTM
Sales, quarterly0.1941.8060.0810.0930.8751.025000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual0.1960.1960.1970.2430.310.3110.3530.3640.54645.541
Period201720182019202020212022202320242025MRQ
Shares, quarterly0.3620.3640.4370.4390.5280.5460.6060.60845.541
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue1.022.072.000.000.303.942.304.510.00
Cost of Goods Sold Incl. D&A---0.000.070.47--1.53
Gross Profit---0.000.233.47---1.53
Selling, General and Administrative Excl. Other55.087.055.639.6518.7749.1877.03121.91113.72
Research and Development43.390.960.291.515.9837.6456.4195.1487.72
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-54.09-4.97-3.63-9.65-18.54-45.71-77.03-120.10-115.25
Interest Expense0.000.000.000.000.00--0.000.00
Unusual Expense0.00-1.32-0.363.300.00-0.411.204.19-
Net Income Before Taxes-52.16-3.53-3.06-12.59-18.25-51.65-77.80-123.01-115.25
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-52.16-3.53-3.06-12.59-18.25-51.65-77.80-123.01-115.25
Net Income From Continuing Operations-52.16-3.53-3.06-12.59-18.25-51.65-77.80-123.01-115.25
Net Income-52.16-3.53-3.06-21.02-44.08-51.65-77.80-123.01-115.25
EPS (Recurring)-3.86-9.79-9.20-55.99-141.99-185.73-354.41-613.98-588.84
EPS (Basic, Before Extraordinaries)-13.07-7.76-8.50-62.92-141.99-184.72-358.26-628.97-588.84
EPS (Diluted)-13.07-7.76-8.50-62.92-141.99-184.72-358.26-628.97-588.84
EBITDA-54.06-4.97-3.63-9.65-18.48-45.24-74.74-117.40-113.72
Non-Operating Income (Expense)1.940.130.210.360.29-6.340.431.280.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense15.440.440.621.076.259.6114.9919.6312.43
Price To Sales Ratio422.261.954.05-96.0217.0840.5216.52-
Gross Margin----78.1188.03---
Operating Margin-5,277.27-239.78-181.40--6,242.42-1,159.67-3,355.18-2,664.72-
Net Margin-5,088.39-170.11-152.85--14,841.08-1,310.17-3,388.59-2,729.27-
Shares Outstanding45.540.550.360.350.310.310.240.200.20
Market Capitalization1,450.041,450.048.208.1928.5474.67104.1875.0774.16

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.001.020.880.090.081.81
Cost of Goods Sold Incl. D&A0.030.000.00-----
Gross Profit-0.030.000.00-----
Selling, General and Administrative Excl. Other48.241.773.211.861.881.761.541.30
Research and Development42.140.000.730.520.350.060.040.06
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-48.27-1.77-3.21-0.84-1.01-1.67-1.460.50
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.00-1.320.000.00
Net Income Before Taxes-46.42-1.75-3.18-0.80-0.98-0.32-1.430.53
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-46.42-1.75-3.18-0.80-0.98-0.32-1.430.53
Net Income From Continuing Operations-46.42-1.75-3.18-0.80-0.98-0.32-1.430.53
Net Income-46.42-1.75-3.18-0.80-0.98-0.32-1.430.53
EPS (Recurring)-3.43-2.89-5.29-1.46-2.12-2.84-3.911.46
EPS (Basic, Before Extraordinaries)-3.43-2.89-5.29-1.46-2.12-0.74-3.911.46
EPS (Diluted)-3.43-2.89-5.29-1.46-2.12-0.74-3.911.46
EBITDA-48.24-1.77-3.21-0.84-1.01-1.67-1.460.50
Non-Operating Income (Expense)1.850.020.030.040.030.030.030.03
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense15.230.050.060.100.120.110.110.12
Price To Sales Ratio422.267.583.272.342.604.113.074.10
Operating Margin----81.76-114.97-1,797.85-1,798.7727.80
Net Margin----77.95-111.54-348.39-1,764.2029.35
Shares Outstanding45.540.610.610.550.530.440.440.36
Market Capitalization1,450.0414.436.574.858.508.957.658.20

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments3.243.237.5713.3853.9654.4097.590.000.00
Short Term Receivables1.000.560.000.100.100.131.470.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets0.400.440.451.341.403.982.130.881.26
Total Current Assets4.634.228.0214.8255.4658.50101.200.881.26
Net Property, Plant & Equipment0.000.000.001.221.4750.2779.756.504.13
Total Investments and Advances5.355.355.350.000.003.844.990.000.00
Intangible Assets0.000.000.00------
Other Assets0.000.000.002.042.412.770.540.030.08
Total Assets9.989.5713.3718.0859.33115.38186.487.405.47
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.006.803.420.000.00
Accounts Payable0.510.391.202.971.831.443.312.781.80
Other Current Liabilities0.390.340.894.669.268.7111.5215.0612.23
Total Current Liabilities0.900.722.097.6311.0916.9518.2517.8514.04
Long Term Debt0.000.000.000.000.0038.9370.500.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.000.000.000.00
Total Liabilities0.900.722.097.6311.0955.8888.7517.8514.04
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity9.098.8511.2910.4548.2559.4997.73-10.45-8.57
Total Shareholders Equity9.098.8511.2910.4548.2559.4997.73-10.45-8.57
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity9.098.8511.2910.4548.2559.4997.73-10.45-8.57
Total Liabilities & Stockholders Equity9.989.5713.3718.0859.33115.38186.487.405.47
Book Value Per Share16.6424.3331.9433.62155.60244.63495.76-53.37-43.77
Tangible Book Value Per Share16.6424.3331.9433.62155.60244.63495.76-53.37-43.77
Full-Time Employees11116323494143140
Price to Book Ratio3.700.930.641.731.551.750.770.62-
Return on Assets-36.07-26.64-80.08-47.14-59.12-51.55-126.89-1,790.88-2,010.10
Return on Equity-39.34-30.36-115.85-62.17-95.87-98.97-281.86--
Return on Invested Capital-38.83-34.54-186.17-421.72-107.05-79.05-73.12--
Quick Ratio5.155.833.851.945.003.455.550.050.09
Current Ratio5.155.833.851.945.003.455.550.050.09

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-78.09-3.53-3.06-5.26-44.08-51.65-77.80-123.01-115.25
Depreciation--0.000.000.070.472.302.701.53
Other Funds (Non Cash)17.680.440.26-11.386.2513.2510.6120.3812.43
Funds from Operations-60.38-3.09-2.79-16.64-37.76-37.92-64.90-99.93-101.29
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital9.36-0.23-1.54-4.60-2.851.41-7.59-2.293.79
Cash from Operating Activities-51.02-3.31-4.33-21.25-40.61-36.52-72.49-102.22-97.50
Capital Expenditures-0.300.000.000.000.00-0.01-1.52-6.89-3.44
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.0010.400.001.461.540.17-
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.300.000.0010.400.001.460.02-6.71-3.44
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock0.253.320.005.020.030.2824.58165.130.00
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock0.253.320.005.020.030.2824.58165.130.00
Proceedsfrom Stock Options3.453.320.005.000.000.0024.25164.620.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.003.510.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow351.920.000.000.000.0030.500.0046.44100.94
Other Financing Activities Uses-28.160.000.000.000.000.000.000.000.00
Cash from Financing Activities352.173.320.005.020.0330.7928.09211.57100.94
Exchange Rate Effect-0.00-0.010.010.000.00-0.01-0.02-
Net Change in Cash300.860.01-4.34-5.81-40.58-4.27-44.39102.620.00
Free Cash Flow-51.31-3.31-4.33-21.25-40.61-36.52-74.01-109.10-100.94
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments456.221.392.823.244.573.01
Short Term Receivables0.000.000.001.000.100.53
Inventories0.000.000.000.000.000.00
Other Current Assets4.430.120.270.400.400.49
Total Current Assets460.651.513.094.635.074.02
Net Property, Plant & Equipment1.330.070.070.000.000.00
Total Investments and Advances0.105.355.355.355.355.35
Intangible Assets0.000.000.000.000.000.00
Other Assets0.000.000.000.000.000.00
Total Assets462.086.938.519.9810.419.37
Short Term Debt Incl. Current Port. of LT Debt0.290.000.000.000.000.00
Accounts Payable1.611.600.460.510.480.46
Other Current Liabilities42.300.251.260.390.400.34
Total Current Liabilities44.201.841.710.900.880.80
Long Term Debt0.980.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.380.000.000.000.000.00
Total Liabilities45.561.841.710.900.880.80
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value24.960.000.000.000.000.00
Common Equity391.565.096.799.099.548.57
Total Shareholders Equity416.535.096.799.099.548.57
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity416.535.096.799.099.548.57
Total Liabilities & Stockholders Equity462.086.938.519.9810.419.37
Book Value Per Share8.608.3711.2116.6418.0719.50
Tangible Book Value Per Share8.608.3711.2116.6418.0719.50
Full-Time Employees-1-1--
Price to Book Ratio3.702.840.970.530.891.04
Return on Assets-22.08-82.29-57.50-36.07-22.77-20.03
Return on Equity-24.48-98.22-67.77-39.34-24.80-22.43
Return on Invested Capital-11.12-34.50-46.78-8.79-10.23-3.78
Quick Ratio10.420.821.805.155.785.03
Current Ratio10.420.821.805.155.785.03

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-72.36-1.75-3.18-0.80-0.98-0.32
Other Funds (Non Cash)17.480.050.060.100.120.11
Funds from Operations-54.85-1.70-3.12-0.70-0.86-0.21
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital8.020.271.94-0.880.59-0.29
Cash from Operating Activities-46.83-1.43-1.18-1.58-0.26-0.50
Capital Expenditures-0.230.00-0.070.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.230.00-0.070.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-0.820.000.820.251.83-0.13
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock-0.820.000.820.251.83-0.13
Proceedsfrom Stock Options-0.820.000.823.450.00-0.13
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow351.920.000.000.000.000.00
Other Financing Activities Uses-28.160.000.000.000.000.00
Cash from Financing Activities351.100.000.820.251.83-0.13
Exchange Rate Effect---0.000.000.00
Net Change in Cash304.04-1.43-0.42-1.331.56-0.63
Free Cash Flow-47.06-1.43-1.24-1.58-0.26-0.50

Revenue breakdown

License2024: 250.00K
License Agreement2024: 1.75M
Total Pharmaceutical Preparations revenue2025: 2.07M
United States2024: 2.00M 2025: 2.07M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.37%0.2M45.0M71.33K
2026-10-150.05%0.0M45.0M41.33K
2026-09-300.03%0.0M41.5M25.53K
2026-09-150.03%0.0M14.4M11.76K
2026-08-143.12%0.0M0.2M3.95K
2026-07-311.38%0.0M0.5M5.14K
2026-07-151.07%0.0M0.5M8.63K
2026-06-301.54%0.0M0.5M653.57K
2026-06-151.48%0.0M0.5M643.60K
2026-05-290.76%0.0M0.5M654.09K
2026-05-150.82%0.0M0.5M654.11K
2026-04-301.89%0.0M0.4M664.52K
2026-04-158.91%0.0M0.4M675.08K
2026-03-313.78%0.0M0.4M215.75K
2026-03-133.12%0.0M0.4M215.64K
2026-02-273.49%0.0M0.4M212.50K
2026-02-134.66%0.0M0.4M212.94K
2026-01-307.16%0.0M0.3M258.50K
2026-01-156.68%0.0M0.3M251.88K
2025-12-315.00%0.0M0.3M52.35K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10SCHEDULE 13GSEC
2026-11-09S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-10-22144Filing for proposed sale of securities under Rule 144.SEC
2026-10-15SCHEDULE 13G/ASEC
2026-10-15DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-11-13SEC
2026-10-07SCHEDULE 13G/ASEC
2026-10-05PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-05SEC
2026-09-23144Filing for proposed sale of securities under Rule 144.SEC
2026-09-22144Filing for proposed sale of securities under Rule 144.SEC
2026-09-18144Filing for proposed sale of securities under Rule 144.SEC
2026-09-18SCHEDULE 13GSEC
2026-09-16SCHEDULE 13GSEC
2026-09-15SCHEDULE 13DSEC
2026-09-11SCHEDULE 13DSEC
2026-09-118-KCurrent report2026-09-08SEC
2026-09-104Statement of changes in beneficial ownership of securities2026-09-09SEC
2026-09-104Statement of changes in beneficial ownership of securities2026-09-09SEC
2026-09-104Statement of changes in beneficial ownership of securities2026-09-09SEC
2026-09-104Statement of changes in beneficial ownership of securities2026-09-09SEC
2026-09-103Initial statement of beneficial ownership of securities2026-09-08SEC
2026-09-103Initial statement of beneficial ownership of securities2026-09-08SEC
2026-09-103Initial statement of beneficial ownership of securities2026-09-08SEC
2026-09-103Initial statement of beneficial ownership of securities2026-09-08SEC
2026-09-103Initial statement of beneficial ownership of securities2026-09-08SEC
2026-09-103Initial statement of beneficial ownership of securities2026-09-08SEC
2026-09-103Initial statement of beneficial ownership of securities2026-09-08SEC
2026-09-103Initial statement of beneficial ownership of securities2026-09-08SEC
2026-08-278-KCurrent report2026-08-26SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Kalehua Capital Management LLC76.27%
BALYASNY ASSET MANAGEMENT L.P.7.33%
FMR LLC7.03%
ADAR1 Capital Management, LLC6.90%
Sanofi4.38%
BRAIDWELL LP3.62%
CITADEL ADVISORS LLC1.38%
VANGUARD CAPITAL MANAGEMENT LLC0.71%
Rangeley Capital, LLC0.56%
HRT FINANCIAL LP0.51%

Funds

Fund% owned
-

OakChart. KRSA. Cached 15 minutes.